GHRS Overview

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is28.60 USD with a low forecast of 19.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

GH Research PLC revenue for the last quarter amounts to -16.70M USD, increased 29.22

GH Research PLC. EPS for the last quarter amounts to -12349000.00 USD, increased 17.94

GH Research PLC (GHRS) has 73 emplpoyees as of March 30 2026.

Today GHRS has the market capitalization of 815.69M USD.